Screener

Net Revenues

Name: ANI Pharmaceuticals Net Revenues by Products & Services
Creator: OpenCapital
License: https://www.opencapital.sh/terms

ANI Pharmaceuticals·Products & Services·10 segments·Rolls up to Total Revenue

Breakdown

Segment	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26
Cortrophin Gel	$52.56M	$59.4M	$52.85M	$81.65M	$101.85M	$111.43M	$75.12M	$117.13M
Generic pharmaceutical products	$78.22M	$78.6M	$98.68M	$90.3M	$94.38M	$100.76M	$105.4M	$99.05M
ILUVIEN and YUTIQ	$3.87M	$27.64M	$16.11M	$22.32M	$16.6M	$19.84M	$19.26M	$18.72M
Brand royalties and other revenues	—	—	—	—	—	—	$21.54M	$17.73M
Brands	—	—	$25.12M	$13.2M	$10.68M	$12.32M	$12.33M	$11.81M
Other generic revenues	—	—	—	—	—	—	$3.82M	$1.61M
Rare Disease and Brands total net revenues	$65.62M	$106.89M	$94.08M	$117.16M	$129.13M	$143.59M	—	—
Generics and Other total net revenues	$82.71M	$83.69M	$103.04M	$94.21M	$98.69M	$103.47M	—	—
Total	$148.33M	$190.57M	$197.12M	$211.37M	$227.81M	$247.06M	$237.46M	$266.04M

Cortrophin GelView metric

ILUVIEN and YUTIQView metric

Rare Disease total net revenuesView metric

Brand royalties and other revenuesView metric

Rare Disease and Brands total net revenuesView metric

Generic pharmaceutical productsView metric

Other generic revenuesView metric

Generics and Other total net revenuesView metric

Unapproved ProductsView metric